We acquire, develop and license innovative drugs to treat pandemic infections. We have expanded to develop a broader portfolio of new therapies to meet the rising burden of critical priority infectious disease. Based at Alderley Park in the North West of England, our work addresses unmet patient needs and will bring new portfolio of drugs into clinical trials to treat patients suffering from life-threatening infections.
Breaking News
Webinar on Infex’s Phase II lead respiratory drug, RESP-X
February 6, 2024
On Jan 31st, Infex Therapeutics held a live webinar, to update on progress with our lead Phase II asset, RESP-X.
Infex to present webinar on lead Phase II respiratory drug RESP-X
January 16, 2024
RESP-X is a potential blockbuster anti-virulence antibody drug to reduce the frequency of debilitating exacerbations in respiratory patients with chronic Pseudomonas aeruginosa (Pa) colonisation.
RESP-X successfully completes Phase I trial and initiates Phase IIa trial in NCFB patients
November 2, 2023
No adverse events reported across all cohorts
Latest News
Webinar on Infex’s Phase II lead respiratory drug, RESP-X
February 6, 2024
On Jan 31st, Infex Therapeutics held a live webinar, to update on progress with our lead…
Infex to present webinar on lead Phase II respiratory drug RESP-X
January 16, 2024
RESP-X is a potential blockbuster anti-virulence antibody drug to reduce the frequency of…
RESP-X successfully completes Phase I trial and initiates Phase IIa trial in NCFB patients
November 2, 2023
No adverse events reported across all cohorts
Approval for dosing final RESP-X Phase Ia cohort and first-in-patient Phase IIa
August 22, 2023
RESP-X continues to exhibit strong safety and tolerability profile
Clinical candidate nominated for COV-X programme
August 8, 2023
COV-X is a novel first-in-class small molecule oral pan-coronavirus antiviral candidate
Interim results demonstrate a favourable safety and tolerability profile for RESP-X in ongoing Phase I clinical trial
April 6, 2023
Accelerates plans for Phase IIa study
Infex strengthens Board with appointment of Professor Colm Leonard as Non-Executive Director
February 1, 2023
Infex Therapeutics is pleased to announce the appointment of Professor Colm Leonard as a…
Infex’s novel AMR drug candidate MET-X receives FDA QIDP designation
January 5, 2023
This designation gives MET-X an accelerated U.S. regulatory pathway and an additional…
Infex enters clinic with lead anti-virulence candidate RESP-X for Pseudomonas aeruginosa
November 21, 2022
Infex Therapeutics, a leading anti-infectives specialist, is pleased to announce the…
Sign up complete!
×Thank you for signing up to The AMR Centre’s mailing list which will ensure a timely flow of information and news.